{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:34:31Z","timestamp":1791909271722,"version":"4.3.4"},"reference-count":196,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor T-cells (CAR-Ts) are known as revolutionary living drugs that have turned the tables of conventional cancer treatments in certain hematologic malignancies such as B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) by achieving US Food and Drug Administration (FDA) approval based on their successful clinical outcomes. However, this type of therapy has not seen the light of victory in the fight against solid tumors because of various restricting caveats including heterogeneous tumor antigen expression and the immunosuppressive tumor microenvironments (TME) that negatively affect the tumor-site accessibility, infiltration, stimulation, activation, and persistence of CAR-Ts. In this review, we explore strategic twists including boosting vaccines and designing implementations that can support CAR-T expansion, proliferation, and tumoricidal capacity. We also step further by underscoring novel strategies for triggering endogenous antitumor responses and overcoming the limitation of poor CAR-T tumor-tissue infiltration and the lack of definitive tumor-specific antigens. Ultimately, we highlight how these approaches can address the mentioned arduous hurdles.<\/jats:p>","DOI":"10.3389\/fimmu.2022.795164","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T05:46:55Z","timestamp":1652248015000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":68,"title":["Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?"],"prefix":"10.3389","volume":"13","author":[{"given":"Pouya","family":"Safarzadeh Kozani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooria","family":"Safarzadeh Kozani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Ahmadi Najafabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohamad Javad","family":"Mirarefin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Rahbarizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The Blockade of Immune Checkpoints in Cancer Immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of Antitumor Immunity by CTLA-4 Blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab Plus Ipilimumab in Advanced Melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of Resistance to Immune Checkpoint Inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-018-2484-0","article-title":"Adoptive Cellular Therapies: The Current Landscape","volume":"474","author":"Rohaan","year":"2019","journal-title":"Virchows Arch"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.3489291","article-title":"A New Approach to the Adoptive Immunotherapy of Cancer With Tumor-Infiltrating Lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-Engineered T Cells in Patients With Refractory Cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-2743","article-title":"FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4(+) T Cell Help in Cancer Immunology and Immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00364","article-title":"Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy","volume":"11","author":"Plesca","year":"2020","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19960401)77:7<1303::Aid-cncr12>3.0.Co;2-5","article-title":"Prognostic Value of Tumor Infiltrating Lymphocytes in the Vertical Growth Phase of Primary Cutaneous Melanoma","volume":"77","author":"Clemente","year":"1996","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/bjc.2013.639","article-title":"Tumour-Infiltrating Lymphocytes Predict for Outcome in HPV-Positive Oropharyngeal Cancer","volume":"110","author":"Ward","year":"2014","journal-title":"Br J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.271","article-title":"The Tumor Microenvironment and Its Role in Promoting Tumor Growth","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.156.2.385","article-title":"Regression of a Disseminated Syngeneic Solid Tumor by Systemic Transfer of Lymphoid Cells Expanded in Interleukin 2","volume":"156","author":"Eberlein","year":"1982","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.7.3902","article-title":"Tumor-Specific CD4+ T Lymphocytes From Cancer Patients are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor","volume":"164","author":"Baxevanis","year":"2000","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.63.0970","article-title":"Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer","volume":"34","author":"Brambilla","year":"2016","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-06-3388","article-title":"High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated With the Absence of Lymph Node Metastases in Patients With Large Early-Stage Cervical Cancer","volume":"67","author":"Piersma","year":"2007","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/imm.12033","article-title":"Differential Requirements of CD4(+) T-Cell Signals for Effector Cytotoxic T-Lymphocyte (CTL) Priming and Functional Memory CTL Development at Higher CD8(+) T-Cell Precursor Frequency","volume":"138","author":"Umeshappa","year":"2013","journal-title":"Immunology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198812223192527","article-title":"Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients With Metastatic Melanoma. A Preliminary Report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.132.4.2123","article-title":"The Systemic Administration of Purified Interleukin 2 Enhances the Ability of Sensitized Murine Lymphocytes to Cure a Disseminated Syngeneic Lymphoma","volume":"132","author":"Donohue","year":"1984","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.16.5449","article-title":"Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1857361","article-title":"Lymphodepletion Strategies to Potentiate Adoptive T-Cell Immunotherapy - What Are We Doing; Where Are We Going","volume":"21","author":"Bechman","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T Cell Immunotherapy for Human Cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.156","article-title":"Tisagenlecleucel\u2014the First Approved CAR-T-Cell Therapy: Implications for Payers and Policy Makers","volume":"15","author":"Prasad","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/d41573-021-00063-1","article-title":"FDA Approves First BCMA-Targeted CAR-T Cell Therapy","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B29","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1001\/jama.2020.15456","article-title":"CAR-T Therapy Is Approved for Mantle Cell Lymphoma","volume":"324","author":"Voelker","year":"2020","journal-title":"Jama"},{"key":"B30","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nrd.2017.196","article-title":"FDA Approves First CAR T Therapy","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/d41573-021-00031-9","article-title":"FDA Approves Fourth CAR-T Cell Therapy","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/2159-8290.Cd-nb2017-155","article-title":"FDA Approves Second CAR T-Cell Therapy","volume":"8","year":"2018","journal-title":"Cancer Discov"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61403-3","article-title":"T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase 1 Dose-Escalation Trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441","article-title":"CD22-Targeted CAR T Cells Induce Remission in B-ALL That Is Naive or Resistant to CD19-Targeted CAR Immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-Up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A Single Dose of Peripherally Infused EGFRvIII-Directed CAR T Cells Mediates Antigen Loss and Induces Adaptive Resistance in Patients With Recurrent Glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.58.0225","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/cancers11010047","article-title":"Chimeric Antigen Receptor T-Cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety-A Systematic Review With Meta-Analysis","volume":"11","author":"Yu","year":"2019","journal-title":"Cancers"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.765097","article-title":"Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24","article-title":"Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T Cells Secreting BiTEs Circumvent Antigen Escape Without Detectable Toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.008","article-title":"Obstacles Posed by the Tumor Microenvironment to T Cell Activity: A Case for Synergistic Therapies","volume":"31","author":"Anderson","year":"2017","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.1mr0520-746r","article-title":"Surmounting the Obstacles That Impede Effective CAR T Cell Trafficking to Solid Tumors","volume":"108","author":"Donnadieu","year":"2020","journal-title":"J Leukoc Biol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101079","article-title":"Novel Antigens of CAR T Cell Therapy: New Roads; Old Destination","volume":"14","author":"Safarzadeh Kozani","year":"2021","journal-title":"Trans Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","article-title":"CAR-T Cell Therapy in T-Cell Malignancies: Is Success a Low-Hanging Fruit","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.627549","article-title":"Strategies for Dodging the Obstacles in CAR T Cell Therapy","volume":"11","author":"Safarzadeh Kozani","year":"2021","journal-title":"Front Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-20-1089","article-title":"In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL","volume":"20","author":"Safarzadeh Kozani","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s12032-020-01416-3","article-title":"Strategies for Having a More Effective and Less Toxic CAR T-Cell Therapy for Acute Lymphoblastic Leukemia","volume":"37","author":"Hashem Boroojerdi","year":"2020","journal-title":"Med Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.2088.2088","article-title":"First Generation Chimeric Antigen Receptor Display Functional Defects In Key Signal Pathways Upon Antigen Stimulation","volume":"116","author":"Duell","year":"2010","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-06-1183","article-title":"A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The Pharmacology of Second-Generation Chimeric Antigen Receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase\/AKT\/Bcl-XL Activation and CD8+ T Cell-Mediated Tumor Eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The Fourth Generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an Old Dog New Tricks: Next-Generation CAR T Cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br J Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1042\/bst20150291","article-title":"Armored CAR T-Cells: Utilizing Cytokines and Pro-Inflammatory Ligands to Enhance CAR T-Cell Anti-Tumour Efficacy","volume":"44","author":"Yeku","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/cancers12051075","article-title":"Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers","volume":"12","author":"Kailayangiri","year":"2020","journal-title":"Cancers"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.262","article-title":"Kinetics of Tumor Destruction by Chimeric Antigen Receptor-Modified T Cells","volume":"22","author":"Anurathapan","year":"2014","journal-title":"Mol Ther"},{"key":"B58","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/jci45817","article-title":"Matrix Architecture Defines the Preferential Localization and Migration of T Cells Into the Stroma of Human Lung Tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J Clin Invest"},{"key":"B59","doi-asserted-by":"publisher","first-page":"10634","DOI":"10.1038\/s41598-019-46938-7","article-title":"Manufacturing and Preclinical Validation of CAR T Cells Targeting ICAM-1 for Advanced Thyroid Cancer Therapy","volume":"9","author":"Vedvyas","year":"2019","journal-title":"Sci Rep"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1172\/jci13853","article-title":"Thymocyte Emigration Is Mediated by Active Movement Away From Stroma-Derived Factors","volume":"109","author":"Poznansky","year":"2002","journal-title":"J Clin Invest"},{"key":"B61","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","article-title":"Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy for Solid Tumors: Lessons Learned and Strategies for Moving Forward","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.256","article-title":"Controlled Extracellular Matrix Degradation in Breast Cancer Tumors Improves Therapy by Trastuzumab","volume":"19","author":"Beyer","year":"2011","journal-title":"Mol Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404","article-title":"Melanoma-Intrinsic \u03b2-Catenin Signalling Prevents Anti-Tumour Immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02293","article-title":"WNT\/\u03b2-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment","volume":"10","author":"Li","year":"2019","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108921","article-title":"Intrinsic \u03b2-Catenin Signaling Suppresses CD8(+) T-Cell Infiltration in Colorectal Cancer","volume":"115","author":"Xue","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12036","article-title":"The Immunosuppressive Tumour Network: Myeloid-Derived Suppressor Cells, Regulatory T Cells and Natural Killer T Cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802430","article-title":"Immunosuppressive Myeloid-Derived Suppressor Cells Can Be Converted Into Immunogenic APCs With the Help of Activated NKT Cells: An Alternative Cell-Based Antitumor Vaccine","volume":"182","author":"Ko","year":"2009","journal-title":"J Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.oraloncology.2016.05.002","article-title":"Overcoming Barriers to Effective Immunotherapy: MDSCs, TAMs, and Tregs as Mediators of the Immunosuppressive Microenvironment in Head and Neck Cancer","volume":"58","author":"Davis","year":"2016","journal-title":"Oral Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02651-3","article-title":"Induction of Systemic Immune Responses and Reversion of Immunosuppression in the Tumor Microenvironment by a Therapeutic Vaccine for Cervical Cancer","volume":"69","author":"Che","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3153","article-title":"Novel Cancer Immunotherapy Agents With Survival Benefit: Recent Successes and Next Steps","volume":"11","author":"Sharma","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T Cells With Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients With Advanced Leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric Antigen Receptor T Cells Persist and Induce Sustained Remissions in Relapsed Refractory Chronic Lymphocytic Leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-016-5023-8","article-title":"Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of Patients With EGFR-Expressing Advanced Relapsed\/Refractory non-Small Cell Lung Cancer","volume":"59","author":"Feng","year":"2016","journal-title":"Sci China Life Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.63","article-title":"GD2-Specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter But Can Be Protected From Activation-Induced Cell Death by PD-1 Blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay5967","article-title":"An RNA Vaccine Drives Expansion and Efficacy of Claudin-CAR-T Cells Against Solid Tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav8692","article-title":"Enhanced CAR-T Cell Activity Against Solid Tumors by Vaccine Boosting Through the Chimeric Receptor","volume":"365","author":"Ma","year":"2019","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1157","article-title":"Enhancing Chimeric Antigen Receptor T-Cell Immunotherapy Against Cancer Using a Nanoemulsion-Based Vaccine Targeting Cross-Presenting Dendritic Cells","volume":"9","author":"Chan","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.03.313","article-title":"CD19 Chimeric Antigen Receptor-Redirected T Cells Combined With Epidermal Growth Factor Receptor Pathway Substrate 8 Peptide-Derived Dendritic Cell Vaccine in Leukemia","volume":"21","author":"Wu","year":"2019","journal-title":"Cytotherapy"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01993","article-title":"Combining Adoptive Cell Therapy With Cytomegalovirus-Based Vaccine Is Protective Against Solid Skin Tumors","volume":"8","author":"Grenier","year":"2017","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-2138","article-title":"Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells","volume":"23","author":"Tanaka","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-1860","article-title":"Dual-Specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-Antigen Setting","volume":"23","author":"Slaney","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-Modified CAR T Cells Co-Opt IL-8 for Maximal Antitumor Efficacy in Solid Tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat Commun"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-14-2458","article-title":"Trafficking of T Cells Into Tumors","volume":"74","author":"Slaney","year":"2014","journal-title":"Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/cancers11050674","article-title":"CAR T-Cells Targeting the Integrin \u03b1v\u03b26 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy Against Several Solid Malignancies","volume":"11","author":"Whilding","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2006.00442.x","article-title":"Immune Resistance Orchestrated by the Tumor Microenvironment","volume":"213","author":"Gajewski","year":"2006","journal-title":"Immunol Rev"},{"key":"B88","article-title":"Ultraviolet B Irradiation Promotes Tumorigenic and Metastatic Properties in Primary Cutaneous Melanoma via Induction of Interleukin 8","volume":"55","author":"Singh","year":"1995","journal-title":"Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209650","article-title":"T Lymphocytes Coexpressing CCR4 and a Chimeric Antigen Receptor Targeting CD30 Have Improved Homing and Antitumor Activity in a Hodgkin Tumor Model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J Immunother"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-11-0351","article-title":"Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T Cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1395997","article-title":"Intra-Tumoral Delivery of CXCL11 via a Vaccinia Virus, But Not by Modified T Cells, Enhances the Efficacy of Adoptive T Cell Therapy and Vaccines","volume":"7","author":"Moon","year":"2018","journal-title":"Oncoimmunology"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.011134","article-title":"Glycoengineering of Chimeric Antigen Receptor (CAR) T-Cells to Enforce E-Selectin Binding","volume":"294","author":"Mondal","year":"2019","journal-title":"J Biol Chem"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-15-0263","article-title":"Augmentation of CAR T-Cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization","volume":"4","author":"Newick","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.2.802","article-title":"Inhibition of Antigen-Specific T Cell Proliferation and Cytokine Production by Protein Kinase A Type I","volume":"169","author":"Aandahl","year":"2002","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201900192","article-title":"Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells","volume":"31","author":"Chen","year":"2019","journal-title":"Adv Mater"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-021-00781-2","article-title":"Enhanced Intratumoural Activity of CAR T Cells Engineered to Produce Immunomodulators Under Photothermal Control","volume":"5","author":"Miller","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"B98","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-019-0511-6","article-title":"Cancer-Cell-Secreted CXCL11 Promoted CD8(+) T Cells Infiltration Through Docetaxel-Induced-Release of HMGB1 in NSCLC","volume":"7","author":"Gao","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1378843","article-title":"Bevacizumab-Mediated Tumor Vasculature Remodelling Improves Tumor Infiltration and Antitumor Efficacy of GD2-CAR T Cells in a Human Neuroblastoma Preclinical Model","volume":"7","author":"Bocca","year":"2017","journal-title":"Oncoimmunology"},{"key":"B100","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ymthe.2019.10.010","article-title":"The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors","volume":"28","author":"Deng","year":"2020","journal-title":"Mol Ther"},{"key":"B101","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten Years of Anti-Vascular Endothelial Growth Factor Therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"B102","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/neuonc\/noaa206","article-title":"NEO100 Enables Brain Delivery of Blood-Brain Barrier-Impermeable Therapeutics","volume":"23","author":"Wang","year":"2020","journal-title":"Neuro Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally Administered B7-H3-Targeted CAR T Cells for Treatment of Atypical Teratoid\/Rhabdoid Tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40425-018-0340-z","article-title":"Durable Regression of Medulloblastoma After Regional and Intravenous Delivery of Anti-HER2 Chimeric Antigen Receptor T Cells","volume":"6","author":"Nellan","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T Cell Infusions for Peritoneal Carcinomatosis Are Superior to Systemic Delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther"},{"key":"B106","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/1078-0432.Ccr-17-2041","article-title":"Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2(+) Breast Cancer Metastasis to the Brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02268","article-title":"Effective Targeting of TAG72(+) Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells","volume":"9","author":"Murad","year":"2018","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional Delivery of CAR T Cells to the Cerebrospinal Fluid for Treatment of Metastatic Medulloblastoma and Ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","article-title":"CRISPR-Cas9 Disruption of PD-1 Enhances Activity of Universal EGFRvIII CAR T Cells in a Preclinical Model of Human Glioblastoma","volume":"7","author":"Choi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional Infusion of HER2-Specific CAR T Cells in Children and Young Adults With Recurrent or Refractory CNS Tumors: An Interim Analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.03.018","article-title":"Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy","volume":"17","author":"Aalipour","year":"2020","journal-title":"Mol Ther Oncol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.05.013","article-title":"Adenovirus-Mediated Specific Tumor Tagging Facilitates CAR-T Therapy Against Antigen-Mismatched Solid Tumors","volume":"487","author":"Tang","year":"2020","journal-title":"Cancer Lett"},{"key":"B113","doi-asserted-by":"publisher","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective Combination Immunotherapy Using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci Transl Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0398-2","article-title":"Interleukin-23 Engineering Improves CAR T Cell Function in Solid Tumors","volume":"38","author":"Ma","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-311456","article-title":"Safety (Toxicity), Pharmacokinetics, Immunogenicity, and Impact on Elements of the Normal Immune System of Recombinant Human IL-15 in Rhesus Macaques","volume":"117","author":"Waldmann","year":"2011","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-189266","article-title":"Safety and Immunologic Effects of IL-15 Administration in Nonhuman Primates","volume":"114","author":"Berger","year":"2009","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A Novel Chimeric Antigen Receptor Containing a JAK-STAT Signaling Domain Mediates Superior Antitumor Effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy of Chronic Lymphocytic Leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.2.600","article-title":"Antitumor and Antimetastatic Activity of IL-23","volume":"171","author":"Lo","year":"2003","journal-title":"J Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.9.5213","article-title":"Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant","volume":"176","author":"Overwijk","year":"2006","journal-title":"J Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-Based Chimeric Antigen Receptors Program Bipolar TH17\/TH1 Cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)00070-4","article-title":"Novel P19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, With Biological Activities Similar as Well as Distinct From IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2011.577093","article-title":"Interleukin-23: A Key Cytokine in Inflammatory Diseases","volume":"43","author":"Duvallet","year":"2011","journal-title":"Ann Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2013.07.004","article-title":"A Balance of Interleukin-12 and -23 in Cancer","volume":"34","author":"Ngiow","year":"2013","journal-title":"Trends Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1172\/jci28508","article-title":"The IL-23\/IL-17 Axis in Inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J Clin Invest"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J Biol Chem"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3246","article-title":"Selective Targeting of Engineered T Cells Using Orthogonal IL-2 Cytokine-Receptor Complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"key":"B130","first-page":"11","article-title":"Managing Toxicities of High-Dose Interleukin-2","volume":"16","author":"Schwartz","year":"2002","journal-title":"Oncol (Williston Park)"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: The First Effective Immunotherapy for Human Cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.kint.2016.11.029","article-title":"Capillary Leak Syndrome: Etiologies, Pathophysiology, and Management","volume":"92","author":"Siddall","year":"2017","journal-title":"Kidney Int"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001645","article-title":"Specific Stimulation of T Lymphocytes With Erythropoietin for Adoptive Immunotherapy","volume":"135","author":"Vinanica","year":"2020","journal-title":"Blood"},{"key":"B134","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0065-2776(06)90002-9","article-title":"Mechanisms of Immune Evasion by Tumors","volume":"90","author":"Drake","year":"2006","journal-title":"Adv Immunol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-0305","article-title":"The Role of Antigen Spreading in the Efficacy of Immunotherapies","volume":"26","author":"Brossart","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","first-page":"eabc6401","DOI":"10.1126\/scitranslmed.abc6401","article-title":"Trispecific CD19-CD20-CD22-Targeting duoCAR-T Cells Eliminate Antigen-Heterogeneous B Cell Tumors in Preclinical Models","volume":"13","author":"Schneider","year":"2021","journal-title":"Sci Transl Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-20-1661","article-title":"Ifn\u03b3 Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity","volume":"11","author":"Alizadeh","year":"2021","journal-title":"Cancer Discov"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2011.572874","article-title":"Bispecific Antibodies Engage T Cells for Antitumor Immunotherapy","volume":"11","author":"Choi","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"B139","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-1625","article-title":"Immunotherapy for Glioblastoma: Adoptive T-Cell Strategies","volume":"25","author":"Choi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.3171\/2018.2.Focus17788","article-title":"Chimeric Antigen Receptor T-Cell Immunotherapy for Glioblastoma: Practical Insights for Neurosurgeons","volume":"44","author":"Choi","year":"2018","journal-title":"Neurosurg Focus"},{"key":"B142","article-title":"Frequent Expression of a Mutant Epidermal Growth Factor Receptor in Multiple Human Tumors","volume":"55","author":"Moscatello","year":"1995","journal-title":"Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-17-0314","article-title":"Improving CART-Cell Therapy of Solid Tumors With Oncolytic Virus-Driven Production of a Bispecific T-Cell Engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.02.016","article-title":"Oncolytic Adenovirus Armed With BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors","volume":"28","author":"Porter","year":"2020","journal-title":"Mol Ther"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0676-7","article-title":"Adoptive Cellular Therapy With T Cells Expressing the Dendritic Cell Growth Factor Flt3L Drives Epitope Spreading and Antitumor Immunity","volume":"21","author":"Lai","year":"2020","journal-title":"Nat Immunol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101159","article-title":"Host Type I IFN Signals Are Required for Antitumor CD8+ T Cell Responses Through CD8{alpha}+ Dendritic Cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J Exp Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.07.005","article-title":"Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model","volume":"18","author":"Klampatsa","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B148","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.4","article-title":"Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression","volume":"23","author":"Curran","year":"2015","journal-title":"Mol Ther"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 Expression in CAR-T Cells Improves Immune Cell Infiltration and CAR-T Cell Survival in the Tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/ni1513","article-title":"Fibroblastic Reticular Cells in Lymph Nodes Regulate the Homeostasis of Naive T Cells","volume":"8","author":"Link","year":"2007","journal-title":"Nat Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.1.424","article-title":"Differing Activities of Homeostatic Chemokines CCL19, CCL21, and CXCL12 in Lymphocyte and Dendritic Cell Recruitment and Lymphoid Neogenesis","volume":"169","author":"Luther","year":"2002","journal-title":"J Immunol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(01)02028-2","article-title":"Interleukin-7: Master Regulator of Peripheral T-Cell Homeostasis","volume":"22","author":"Fry","year":"2001","journal-title":"Trends Immunol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.7.901","article-title":"EBI1-Ligand Chemokine (ELC) Attracts a Broad Spectrum of Lymphocytes: Activated T Cells Strongly Up-Regulate CCR7 and Efficiently Migrate Toward ELC","volume":"10","author":"Yoshida","year":"1998","journal-title":"Int Immunol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02853-3","article-title":"Enhanced Anti-Tumor Efficacy of IL-7\/CCL19-Producing Human CAR-T Cells in Orthotopic and Patient-Derived Xenograft Tumor Models","volume":"70","author":"Goto","year":"2021","journal-title":"Cancer Immunol Immunother CII"},{"key":"B156","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-Secreting CAR-T Cell Therapy for Tumors With Positive Glypican-3 or Mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.13345\/j.cjb.200106","article-title":"[Construction and Function of Glypican-3-Targeted Fourth-Generation Chimeric Antigen Receptor T Cells (Secreting IL-7 and CCL19)]","volume":"36","author":"Huang","year":"2020","journal-title":"Sheng wu gong cheng xue bao = Chin J Biotechnol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2013.11.003","article-title":"Biology of IL-36 Cytokines and Their Role in Disease","volume":"25","author":"Gresnigt","year":"2013","journal-title":"Semin Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-439026","article-title":"IL-36 Signaling Amplifies Th1 Responses by Enhancing Proliferation and Th1 Polarization of Naive CD4+ T Cells","volume":"120","author":"Vigne","year":"2012","journal-title":"Blood"},{"key":"B160","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ccell.2015.07.014","article-title":"IL-36\u03b3 Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses","volume":"28","author":"Wang","year":"2015","journal-title":"Cancer Cell"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0874-1","article-title":"Cytokine IL-36\u03b3 Improves CAR T-Cell Functionality and Induces Endogenous Antitumor Response","volume":"35","author":"Li","year":"2020","journal-title":"Leukemia"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and Through Activation of the Endogenous Immune System","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T Cells Releasing IL-18 Convert to T-Bet(high) FoxO1(low) Effectors That Exhibit Augmented Activity Against Advanced Solid Tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201901809R","article-title":"IL-18R-Dependent and Independent Pathways Account for IL-18-Enhanced Antitumor Ability of CAR-T Cells","volume":"34","author":"Huang","year":"2020","journal-title":"FASEB J"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.11.6193","article-title":"Role of TNF Receptor-Associated Factor 2 and P38 Mitogen-Activated Protein Kinase Activation During 4-1BB-Dependent Immune Response","volume":"165","author":"Cannons","year":"2000","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B167","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev.immunol.23.021704.115839","article-title":"TNF\/TNFR Family Members in Costimulation of T Cell Responses","volume":"23","author":"Watts","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2004-04-1596","article-title":"The CD28 Family: A T-Cell Rheostat for Therapeutic Control of T-Cell Activation","volume":"105","author":"Riley","year":"2005","journal-title":"Blood"},{"key":"B169","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.addr.2006.03.011","article-title":"Formulation and Delivery Issues for Monoclonal Antibody Therapeutics","volume":"58","author":"Daugherty","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M506881200","article-title":"Production of Recombinant Human Trimeric CD137L (4-1bbl). Cross-Linking Is Essential to Its T Cell Co-Stimulation Activity","volume":"280","author":"Rabu","year":"2005","journal-title":"J Biol Chem"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1126\/science.7678351","article-title":"Tumor Rejection After Direct Costimulation of CD8+ T Cells by B7-Transfected Melanoma Cells","volume":"259","author":"Townsend","year":"1993","journal-title":"Science"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1521-4141(199803)28:03<1116::Aid-immu1116>3.0.Co;2-a","article-title":"Amplification of Tumor Immunity by Gene Transfer of the Co-Stimulatory 4-1BB Ligand: Synergy With the CD28 Co-Stimulatory Pathway","volume":"28","author":"Melero","year":"1998","journal-title":"Eur J Immunol"},{"key":"B173","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.162.8.5003","article-title":"4-1BBL Cooperates With B7-1 and B7-2 in Converting a B Cell Lymphoma Cell Line Into a Long-Lasting Antitumor Vaccine","volume":"162","author":"Guinn","year":"1999","journal-title":"J Immunol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/ni1029","article-title":"Priming of Naive T Cells Inside Tumors Leads to Eradication of Established Tumors","volume":"5","author":"Yu","year":"2004","journal-title":"Nat Immunol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-03-3911","article-title":"Adenovirus Vector-Mediated In Vivo Gene Transfer of OX40 Ligand to Tumor Cells Enhances Antitumor Immunity of Tumor-Bearing Hosts","volume":"64","author":"Andarini","year":"2004","journal-title":"Cancer Res"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/nm1676","article-title":"T Cell-Encoded CD80 and 4-1BBL Induce Auto- and Transcostimulation, Resulting in Potent Tumor Rejection","volume":"13","author":"Stephan","year":"2007","journal-title":"Nat Med"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"B178","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccr.2013.12.004","article-title":"Targeting the Tumor Microenvironment With Interferon-\u03b2 Bridges Innate and Adaptive Immune Responses","volume":"25","author":"Yang","year":"2014","journal-title":"Cancer Cell"},{"key":"B179","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood-2018-99-117737","article-title":"A Phase I First-In-Human Clinical Trial of CD19-Targeted 19-28z\/4-1BBL \"Armored\" CAR T Cells in Patients With Relapsed or Refractory NHL and CLL Including Richter\u2019s Transformation","volume":"132","author":"Park","year":"2018","journal-title":"Blood"},{"key":"B180","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","article-title":"The Biology of NKT Cells","volume":"25","author":"Bendelac","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1038\/nri2743","article-title":"iNKT Cell Autoreactivity: What Is \u2019Self\u2019 and How Is It Recognized","volume":"10","author":"Gapin","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.09.008","article-title":"Immune Networks and Therapeutic Targeting of iNKT Cells in Cancer","volume":"40","author":"Fujii","year":"2019","journal-title":"Trends Immunol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-05-0877","article-title":"Increased Intratumor Valpha24-Positive Natural Killer T Cells: A Prognostic Factor for Primary Colorectal Carcinomas","volume":"11","author":"Tachibana","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.38.8819","article-title":"Circulating Invariant Natural Killer T-Cell Numbers Predict Outcome in Head and Neck Squamous Cell Carcinoma: Updated Analysis With 10-Year Follow-Up","volume":"30","author":"Schneiders","year":"2012","journal-title":"J Clin Oncol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.01.009","article-title":"Anti-Tumor Immune Responses Induced by iNKT Cell-Based Immunotherapy for Lung Cancer and Head and Neck Cancer","volume":"140","author":"Motohashi","year":"2011","journal-title":"Clin Immunol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-0600","article-title":"Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial","volume":"23","author":"Exley","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(02)02323-2","article-title":"Distinct Subsets of Human Valpha24-Invariant NKT Cells: Cytokine Responses and Chemokine Receptor Expression","volume":"23","author":"Kim","year":"2002","journal-title":"Trends Immunol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1172\/jci59535","article-title":"IL-15 Protects NKT Cells From Inhibition by Tumor-Associated Macrophages and Enhances Antimetastatic Activity","volume":"122","author":"Liu","year":"2012","journal-title":"J Clin Invest"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.101","article-title":"\u03b3\u03b4 T Cells in Homeostasis and Host Defence of Epithelial Barrier Tissues","volume":"17","author":"Nielsen","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00985","article-title":"Human \u03b3\u03b4 T-Cell Control of Mucosal Immunity and Inflammation","volume":"9","author":"McCarthy","year":"2018","journal-title":"Front Immunol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237123","article-title":"The MHC Class Ib Protein ULBP1 Is a Nonredundant Determinant of Leukemia\/Lymphoma Susceptibility to Gammadelta T-Cell Cytotoxicity","volume":"115","author":"Lan\u00e7a","year":"2010","journal-title":"Blood"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.01.031","article-title":"Gamma Delta T Cells Kill Myeloma Cells by Sensing Mevalonate Metabolites and ICAM-1 Molecules on Cell Surface","volume":"354","author":"Uchida","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900101","article-title":"Reduced Expression of the Mevalonate Pathway Enzyme Farnesyl Pyrophosphate Synthase Unveils Recognition of Tumor Cells by Vgamma9Vdelta2 T Cells","volume":"182","author":"Li","year":"2009","journal-title":"J Immunol"},{"key":"B194","first-page":"37","article-title":"Induction of Gamma Delta T Cells Using Zoledronate Plus Interleukin-2 in Patients With Metastatic Cancer","volume":"58","author":"Nagamine","year":"2009","journal-title":"Hiroshima J Med Sci"},{"key":"B195","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-1-4419-1050-9_2","article-title":"Activation of \u03b3\u03b4 T Cells by Bisphosphonates","volume":"658","author":"Thompson","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.12.001","article-title":"Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity With Retention of Cross Presentation","volume":"26","author":"Capsomidis","year":"2018","journal-title":"Mol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.795164\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T21:44:19Z","timestamp":1675547059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.795164\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":196,"alternative-id":["10.3389\/fimmu.2022.795164"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.795164","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]},"article-number":"795164"}}